A breakthrough in HIV treatment, which gives women 100% protection through a twice-yearly injection, is unlikely to be available in Africa soon because of high prices and short supply. South African scientists say low- and middle-income countries face a wait of three years or more.

The “miracle” pre-exposure prophylaxis (PrEP) drug, lenacapavir, which recently underwent a successful trial in South Africa and Uganda, was approved by the Food & Drug Administration in December 2022 for use in the US. It has also been approved in Canada, the UK and the EU. ..

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.